Jiangsu Dingtai Pharmaceutical Research
Offering disease model and pharmacodynamics research, drug policy and safety assessment, and clinical and laboratory services, along with a high-quality laboratory animal supply system
At a glance
- Status
- Operational
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 23.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Research and Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2023 | $28M | $688M | Hillhouse Capital · China Pacific Insurance · Lingang Science and Technology Innovation · Howbuy Asset Management | ↗ |
| LATE VCOther financing | Jan 2021 | $138M | $550M | Qiming Venture Partners · L Squared Capital Partners · Boquan Capital · Xiaochi Capital | — |
Growth signals
Latest recorded traffic for Jiangsu Dingtai Pharmaceutical Research is 20 monthly website visits, down 90% over the last three months. Jiangsu Dingtai Pharmaceutical Research's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jiangsu Dingtai Pharmaceutical Research in the Nanjing City ecosystem
The Jiangsu Dingtai Pharmaceutical Research office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- NINanjing Dingye Investment
- BMBeijing Jinlinghui Investment Management
Huafu Securities
Series B and later23 investors entered at this stage
Qiming Venture Partners
L Squared Capital Partners
Boquan Capital- XCXiaochi Capital
- HIHuai Kee Investment
- SISeasonal investment
IDG Capital
Hillhouse Capital
Lilly Asia Ventures
Loyal Valley Capital
Huatai Zijin Investment
3H Health Investment- JMJiangsu Ruihua Investment Management
- YCYuansheng Venture Capital
- SFSuzhou Fund
- LFLingang Blue Bay Fund
- GIGuofu Innovation
Nanjing Venture Capital
Legend Capital
China Pacific Insurance- LILingang Science and Technology Innovation
Howbuy Asset Management
Highlight Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jiangsu Dingtai Pharmaceutical Research on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jiangsu Dingtai Pharmaceutical Research’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









